Scarica l'app Stockscreener
10.69
2.49%
0.26
Dopo l'orario di chiusura:
10.74
0.05
+0.47%
Precedente Chiudi:
$10.43
Aprire:
$10.69
Volume 24 ore:
97,170
Relative Volume:
0.51
Capitalizzazione di mercato:
$348.07M
Reddito:
$65.42M
Utile/perdita netta:
$-32.96M
Rapporto P/E:
-8.4173
EPS:
-1.27
Flusso di cassa netto:
$-19.87M
1 W Prestazione:
-2.82%
1M Prestazione:
-13.16%
6M Prestazione:
+43.88%
1 anno Prestazione:
-21.57%
Intervallo 1D:
$10.49
$10.82
Intervallo di 1 settimana:
$9.56
$11.09
Portata 52W:
$5.45
$15.77
Neuropace Inc Stock (NPCE) Company Profile
Nome
Neuropace Inc
Settore
Industria
Telefono
(650) 237-2700
Indirizzo
455 N. BERNARDO AVENUE, MOUNTAIN VIEW
Confronta NPCE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NPCE
Neuropace Inc
|
10.69 | 348.07M | 65.42M | -32.96M | -19.87M | -1.27 |
|
ABT
Abbott Laboratories
|
126.71 | 219.76B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
97.16 | 143.39B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
369.53 | 141.00B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
93.07 | 119.34B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
69.29 | 40.74B | 5.72B | 4.17B | 259.90M | 6.97 |
Neuropace Inc Stock (NPCE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-21 | Iniziato | UBS | Buy |
| 2024-03-14 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-01-30 | Iniziato | Leerink Partners | Outperform |
| 2023-11-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-08-24 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2023-02-22 | Iniziato | Lake Street | Buy |
| 2022-04-06 | Iniziato | Wolfe Research | Outperform |
| 2022-01-19 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-01-07 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-11 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-08-18 | Iniziato | Robert W. Baird | Outperform |
| 2021-05-17 | Iniziato | JP Morgan | Overweight |
| 2021-05-17 | Iniziato | Morgan Stanley | Overweight |
| 2021-05-17 | Iniziato | SVB Leerink | Outperform |
| 2021-05-17 | Iniziato | Wells Fargo | Overweight |
Mostra tutto
Neuropace Inc Borsa (NPCE) Ultime notizie
NeuroPace’s SWOT analysis: stock poised for growth amid expanding market - Investing.com India
Analysts Set Expectations for NeuroPace FY2025 Earnings - MarketBeat
NeuroPACE at Leerink’s Conference: Strategic Growth and Challenges By Investing.com - Investing.com Canada
Cantor Fitzgerald maintains NeuroPace stock target at $20 By Investing.com - Investing.com Canada
Cantor Fitzgerald maintains NeuroPace stock target at $20 - Investing.com
NeuroPace (NASDAQ:NPCE) Announces Quarterly Earnings Results - MarketBeat
Cantor Fitzgerald Issues Positive Forecast for NeuroPace (NASDAQ:NPCE) Stock Price - MarketBeat
Cantor Fitzgerald Expects Increased Earnings for NeuroPace - Defense World
NeuroPace, Inc. (NASDAQ:NPCE) Annual Results: Here's What Analysts Are Forecasting For This Year - Simply Wall St
NeuroPace (NASDAQ:NPCE) Stock Price Expected to Rise, Cantor Fitzgerald Analyst Says - Defense World
NeuroPace Full Year 2024 Earnings: EPS Beats Expectations - Yahoo Finance
NeuroPace: Strong Financial Performance and Strategic Initiatives Drive Buy Rating - TipRanks
NeuroPace, Inc. Reports Strong 2024 Growth Despite Challenges - TipRanks
Cantor raises NeuroPace stock price target to $20, maintains overweight - Investing.com India
What 4 Analyst Ratings Have To Say About NeuroPace - Benzinga
NeuroPace, Inc. (NASDAQ:NPCE) Q4 2024 Earnings Call Transcript - Insider Monkey
Cantor raises NeuroPace stock price target to $20, maintains overweight By Investing.com - Investing.com South Africa
NeuroPace Q4 2024 revenue increases 19% to USD 21.5M - Medical Buyer
NeuroPace Inc.: Q4 Earnings Snapshot - Midland Daily News
NeuroPace Inc (NPCE) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
NeuroPace Reports Strong Growth and Strategic Advancements - TipRanks
Earnings call transcript: Neuropace Q4 2024 results beat forecasts - Investing.com India
NeuroPace reports Q4 EPS (18c), consensus (22c) - TipRanks
Neuropace Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings call transcript: Neuropace Q4 2024 results beat forecasts By Investing.com - Investing.com UK
NeuroPace Inc SEC 10-K Report - TradingView
Neuropace earnings beat by $0.07, revenue topped estimates - Investing.com Australia
NeuroPace Reports Fourth Quarter and Full Year 2024 Financial Results -March 04, 2025 at 04:54 pm EST - Marketscreener.com
NeuroPace stock rises on Q4 earnings beat, strong 2025 outlook By Investing.com - Investing.com Australia
NeuroPace stock rises on Q4 earnings beat, strong 2025 outlook - Investing.com India
NeuroPace Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
NeuroPace Inc.: Q4 Earnings Snapshot -March 04, 2025 at 04:25 pm EST - Marketscreener.com
UPDATENeuroPace to Present at the Leerink Partners Global Healthcare Conference - The Manila Times
When Will NeuroPace Reveal Its Next Strategic Moves? Key Investor Conference Date Set - StockTitan
NeuroPace, Inc. to Present at Leerink Partners 2025 Global Healthcare Conference - Nasdaq
UPDATE – NeuroPace to Present at the Leerink Partners Global Healthcare Conference - Yahoo Finance
UPDATE – NeuroPace to Present at the Leerink Partners Global Healthcare Conference - GlobeNewswire Inc.
NeuroPace to Present at the Leerink Partners Global Healthcare Conference - The Manila Times
How Will NeuroPace Position Its Epilepsy Treatment Future at Leerink's Healthcare Conference? - StockTitan
UPDATE – NeuroPace To Present At The Leerink Partners Global Healthcare Conference - Barchart
NeuroPace (NPCE) Projected to Post Earnings on Tuesday - Defense World
Insider Selling: NeuroPace, Inc. (NASDAQ:NPCE) Insider Sells 78,334 Shares of Stock - MarketBeat
When the Price of (NPCE) Talks, People Listen - Stock Traders Daily
NeuroPace (NPCE) to Release Quarterly Earnings on Tuesday - MarketBeat
Neuropace Inc Azioni (NPCE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.23%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):